Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Devlin

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Blood|February 14, 2013
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomasJake Shortt, Benjamin P Martin, Andrea Newbold, et al.
Nature Communications|November 24, 2022
A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometryNishant K Singh, Jesus A Alonso, Jason R Devlin, et al.
Cancer Discovery|October 23, 2015
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven LymphomaJennifer R Devlin, Katherine M Hannan, Nadine Hein, et al.
The EMBO Journal|September 18, 2020
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesisEric P Kusnadi, Anna S Trigos, Carleen Cullinane, et al.
Molecular Cell|August 26, 2025
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongationJennifer R Devlin, Ben Martin, Nenad Bartonicek, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Science Advances|September 12, 2020
CDK13 cooperates with CDK12 to control global RNA polymerase II processivityZheng Fan, Jennifer R Devlin, Simon J Hogg, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Blood|February 14, 2013
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomasJake Shortt, Benjamin P Martin, Andrea Newbold, et al.
Nature Communications|November 24, 2022
A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometryNishant K Singh, Jesus A Alonso, Jason R Devlin, et al.
Cancer Discovery|October 23, 2015
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven LymphomaJennifer R Devlin, Katherine M Hannan, Nadine Hein, et al.
The EMBO Journal|September 18, 2020
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesisEric P Kusnadi, Anna S Trigos, Carleen Cullinane, et al.
Molecular Cell|August 26, 2025
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongationJennifer R Devlin, Ben Martin, Nenad Bartonicek, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Science Advances|September 12, 2020
CDK13 cooperates with CDK12 to control global RNA polymerase II processivityZheng Fan, Jennifer R Devlin, Simon J Hogg, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 16